Maia Hugo, Casoy Julio, Pimentel Kleber, Correia Tania, Athayde Célia, Cruz Thomaz, Coutinho Elsimar Metzker
Centro de Pesquisas e Assistência em Reprodução Humana (CEPARH), 40210-341 Salvador, Bahia, Brazil.
Contraception. 2008 Dec;78(6):479-85. doi: 10.1016/j.contraception.2008.07.002. Epub 2008 Aug 9.
The study was conducted to evaluate vascular endothelial growth factor (VEGF), Cox-2 and aromatase expression in the endometrium of uteri with myomas and other associated pathologies.
Hysteroscopy was performed in 118 women of reproductive age with myomas and menorrhagia, 40 of whom were using a pill containing 75 mcg gestodene+30 mcg ethinylestradiol. Aromatase p450, VEGF and Cox-2 expression was detected using immunohistochemistry. Fisher's Exact Test and the Mann-Whitney test were used in the statistical analysis, with significance established at p<.05.
In patients with myomas and menorrhagia, associated pathologies such as adenomyosis, endometrial polyps and endometriosis were found in 32%, 12% and 17% of cases, respectively. Aromatase, Cox-2 and VEGF expression was greater during the proliferative phase compared to the luteal phase of the cycle or following oral contraceptive use.
Endogenous progesterone or combined oral contraceptives are potent inhibitors of VEGF, aromatase and Cox-2 expression in the endometrium of patients with myomas and menorrhagia.
本研究旨在评估患有肌瘤及其他相关病变的子宫内膜中血管内皮生长因子（VEGF）、Cox - 2和芳香化酶的表达情况。
对118例患有肌瘤且月经过多的育龄妇女进行宫腔镜检查，其中40例正在使用含75微克孕二烯酮 + 30微克炔雌醇的避孕药。采用免疫组织化学法检测芳香化酶p450、VEGF和Cox - 2的表达。统计分析采用Fisher精确检验和Mann - Whitney检验，以p <.05为有统计学意义。
在患有肌瘤且月经过多的患者中，分别有32%、12%和17%的病例发现合并有子宫腺肌病、子宫内膜息肉和子宫内膜异位症等相关病变。与月经周期的黄体期或使用口服避孕药后相比，增殖期芳香化酶、Cox - 2和VEGF的表达更高。
内源性孕酮或复方口服避孕药是患有肌瘤且月经过多患者子宫内膜中VEGF、芳香化酶和Cox - 2表达的有效抑制剂。
